5,256 Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by Profund Advisors LLC

Posted by George Bondi on Nov 3rd, 2026

Profund Advisors LLC lifted its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) by 208.0% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,783 shares of the specialty pharmaceutical company’s stock after purchasing an additional 5,256 shares during the period. Profund Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $1,802,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. USA Financial Formulas bought a new stake in Jazz Pharmaceuticals during the first quarter valued at about $25,000. Pension & Wealth Management Advisors Inc. purchased a new stake in Jazz Pharmaceuticals in the third quarter worth about $32,000. Ameritas Advisory Services LLC bought a new stake in Jazz Pharmaceuticals during the 2nd quarter worth approximately $47,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter valued at $61,000. Finally, Elevation Wealth Partners LLC raised its holdings in Jazz Pharmaceuticals by 156.4% during the third quarter. Elevation Wealth Partners LLC now owns 259 shares of the specialty pharmaceutical company’s stock valued at $60,000 after acquiring an additional 158 shares during the period. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ opened at $214.44 on Tuesday. Jazz Pharmaceuticals PLC has a 52 week low of $128.80 and a 52 week high of $266.38. The stock has a market capitalization of $13.92 billion, a P/E ratio of 8.88, a PEG ratio of 0.41 and a beta of 0.37. The firm has a fifty day simple moving average of $231.16 and a two-hundred day simple moving average of $216.50. The company has a quick ratio of 1.58, a current ratio of 1.78 and a debt-to-equity ratio of 0.69.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last posted its earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.05) by $0.17. The firm had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.21 billion. Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The business’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the firm posted $8.13 EPS. On average, analysts expect that Jazz Pharmaceuticals PLC will post 10.87 earnings per share for the current fiscal year.

Key Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

Positive Sentiment: Jazz reported third-quarter revenue of approximately $1.24 billion, up 10.4% year over year and ahead of the roughly $1.21 billion analyst estimate. The company also raised its full-year 2026 total revenue guidance, signaling confidence in commercial execution. Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
Positive Sentiment: Xywav revenue increased 12% year over year, with 425 net patient additions during the quarter. Jazz also launched Ziihera in first-line HER2-positive metastatic or unresectable gastric and esophageal cancer, expanding its commercial opportunity. Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
Positive Sentiment: The completed Actio acquisition adds the ABS-1230 candidate to Jazz’s rare-epilepsy pipeline. Separately, the company plans to present additional neuro-oncology research and Phase 3 ACTION trial progress at the Society for Neuro-Oncology meeting, potentially providing future clinical catalysts. Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026
Neutral Sentiment: Management characterized the quarter as evidence of sustained execution and discussed the results during the earnings call. Investors will likely focus on the details behind the higher revenue outlook, product trends and pipeline priorities. Jazz Pharmaceuticals Q3 2026 Earnings Call Transcript
Negative Sentiment: Jazz posted a quarterly loss of $3.88 per share, although it was better than the consensus loss estimate of approximately $4.05-$4.09. The result compares with earnings of $8.13 per share a year earlier, creating a significant year-over-year deterioration that may be weighing on the stock. Jazz Pharmaceuticals Reports Q3 Loss, Tops Revenue Estimates

Insider Buying and Selling

In related news, EVP Robert Iannone sold 76,921 shares of the firm’s stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $249.70, for a total value of $19,207,173.70. Following the completion of the sale, the executive vice president directly owned 65,686 shares in the company, valued at $16,401,794.20. This trade represents a 53.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $240.94, for a total transaction of $289,128.00. Following the completion of the sale, the executive vice president directly owned 47,671 shares in the company, valued at approximately $11,485,850.74. This represents a 2.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 94,121 shares of company stock valued at $23,337,922. Insiders own 4.10% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on JAZZ shares. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a “buy” rating in a report on Wednesday, August 26th. Royal Bank Of Canada reduced their target price on Jazz Pharmaceuticals from $299.00 to $296.00 and set an “outperform” rating on the stock in a report on Thursday, October 8th. Stifel Nicolaus set a $275.00 target price on Jazz Pharmaceuticals in a research report on Tuesday, August 4th. Canaccord Genuity Group set a $300.00 target price on Jazz Pharmaceuticals in a research report on Wednesday, August 26th. Finally, Wells Fargo & Company increased their price target on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $292.05.

Check Out Our Latest Report on JAZZ

Jazz Pharmaceuticals Company Profile

(Free Report)

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.